Lanreotide
Lanreotide was the drug used in PLD clinical trials in the Netherlands by Dr. Drenth. Octreotide, sandostatin LAR, lanreotide, vapreotide, somatostatin are names for a similar drug. From the above pulldown menu one can select a webpage with more information on octreotide. The menu below will give links to many articles from the Netherlands' experience using Lanreotide. It was given subcutaneously every 28 days; this was a (6) six month study with lanreotide showing a percentage reduction in PLD Polycystic Liver Disease. The next article is a case study of two (2) Polycystic Liver Disease patients that had a significant reduction in their liver cyst volume and a diminishing of ascites. Dr. Drenth has another lanreotide clinical trial; all participants will receive 90 mg of lanreotide every 28 days. Our unique responses to lanreotide can vary from individual to individual.
A 2014 study in the PKD animal model shows Tolvaptan + octreotide to have a synergistic effect on cyst formation, better than either one alone.